Brief: Sensorion Development Milestone For Sens-501 Program

Sensorion SA

20/09/2023 06:57

Sept 20 (Reuters) - Sensorion SA  ALSEN.PA :
    * DEVELOPMENT MILESTONE ACHIEVED FOR SENS-501 (OTOF-GT)
PROGRAM
WITH SUBMISSION OF CLINICAL TRIAL APPLICATIONS IN UK AND IN
EUROPE
    * POSITIVE PRELIMINARY EFFICACY RESULTS OF PROOF-OF-CONCEPT
PHASE
2A CLINICAL TRIAL OF SENS-401
    * EXTENDED CASH RUNWAY UNTIL END OF SEPTEMBER 2024
    * COMPLETION OF A PRIVATE PLACEMENT OF EUR 35MILLION LED BY
US-BASED HEALTHCARE INVESTOR, REDMILE GROUP, AND RENEWED SUPPORT
FROM EXISTING SHAREHOLDERS, INVUS AND SOFINNOVA PARTNERS;
EXTENDED CASH RUNWAY UNTIL END OF SEPTEMBER 2024
    * CASH & CASH EQUIVALENTS AMOUNTED TO EUR 14.4 MILLION AS OF
JUNE
30, 2023, COMPARED TO EUR 26.2 MILLION AS OF DECEMBER 31, 2022
    * NET LOSS WAS -€12.3 MILLION FOR HALF-YEAR 2023, AT THE
SAME
LEVEL AS FOR HALF-YEAR 2022
    * G&A EXPENSES WERE €2.6 MILLION FOR HALF-YEAR 2023,
COMPARED TO
€3.0 MILLION FOR THE SAME PERIOD IN 2022
    * COMPANY EXPECTS TO BE ABLE TO FUND ITS OPERATIONS UNTIL
END OF
Q3 2024

Source text for Eikon:  ID:nBwMF1mLa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))